The Alliance of Specialty Medicine advocates for sound federal health care policy that fosters patient access to the highest quality specialty care and improves timely access to high-quality medical care for all Americans. As patient and physician advocates, the Alliance welcomes the opportunity to proactively participate in the formation of health and Medicare policy.
Access to Specialty Care
The Alliance of Specialty Medicine supports opportunities to improve the prior authorization process to ensure safe, timely, and affordable access to care for patients. The current prior authorization process can be burdensome for patients, providers, and insurance plans, and we seek to improve the process. The lack of industry-wide standards for the use of electronic prior authorization further complicates this process.
The Medicare program requires Medicare Advantage (MA) plans to provide coverage equivalent to traditional fee-for-service (FFS) in Medicare Part A and Part B. Furthermore, the Centers for Medicare & Medicaid Services (CMS) instructions to plans preclude them from using prior authorization and other utilization control tools in a manner that imposes inappropriate barriers to access. Despite these requirements, MA plans are overusing and misusing these practices because CMS has not provided adequate guidance on what constitutes appropriate prior authorization, nor does the agency in its oversight role collect adequate data to assess the utility of these programs and their impact on patient access to care. Recognizing the problems with prior authorization in the MA program, Reps. Phil Roe, MD, (R-Tenn.) and Ami Bera, MD, (D-Calif.), spearheaded a letter in 2018 that was signed by 103 bipartisan members of the House of Representatives urging CMS to improve how prior authorization works under MA.
In step therapy, insurers require patients, sometimes even those stable on a certain medication, to try and fail medications before agreeing to cover the initial therapy prescribed by the health care provider. This practice jeopardizes the health of patients and the physician-patient relationship. A 2018 article in the Food and Drug Law Journal discusses that such policy has been shown not to save money in the long run due to patient complications. Appealing step therapy protocols can be very timely and burdensome for physicians and patients and can take months to resolve — all while the disease is progressing.
In 2018, the Alliance was troubled to hear of CMS’ recent decision to allow Medicare Advantage plans to institute step therapy for Part B drugs starting in 2019. The Administration proposed this significant change via a memo that has no formal commenting opportunity and leaves many implementation questions unanswered, including questions about how patient access will be protected. The Alliance wrote to CMS Administrator Seema Verma, expressing its opposition to this policy change because of its lack of protections for vulnerable patients who need access to Part B medications.
The Alliance supports federal legislation to address this issue, including H.R.2279, the Safe Step Act.
Medical Liability Reform
The Alliance supports comprehensive, meaningful medical liability reform that reduces growth in health care costs, stabilizes professional liability insurance premiums, preserves access to specialty care, and encourages physician engagement in meaningful quality improvement activities. We support legislation that will help achieve health system savings by reducing the incentives for defensive medicine and protect physicians from unaffordable liability premiums. Congress should enact medical liability reform based on the California or Texas models, which include reasonable limits on non‐economic damages. In addition to these health care cost savings, such reforms will also improve patient access to specialty care — particularly high-risk specialties. The following documents represent the Alliance’s position on the issue of medical liability reform:
The Alliance of Specialty Medicine maintains that a specialty physician may prescribe or administer any legally marketed product for an off-label use within the authorized practice of medicine where the physician exercises appropriate medical judgment and it is in the best interests of the patient. If specialty physicians use a product for an indication not in the approved or cleared labeling, they have the responsibility: (1) to be well informed about the product; (2) to base its use on a firm scientific rationale and sound medical evidence; and (3) to maintain awareness of the product’s use and effects. Specialty physicians should appropriately counsel patients about the benefits and risks of the proposed treatment, and whether alternative treatments might be available. Specialty physicians are encouraged to notify the relevant agency or institution of adverse events related to the use of medical products. The following documents represent the Alliance’s position on the issue of off-label use:
- Physician-Directed Applications Position Statement
- FDA Public Hearing Testimony – Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products
Patients face access to care barriers due to narrow health plan networks. Many times, unknown to patients, entire specialties are excluded from health plans or the number and mix of specialists and subspecialists are not adequate to meet the needs of the insured population. Networks should be sufficiently robust to ensure that an appropriate number of specialists and subspecialists per enrollee are available. Additionally, network directories should be updated in real-time and provide patients with clear, concise, and accurate information. Finally, decisions to remove a physician from the network without cause should not be made in the middle of a contract year. Congress and the Administration should ensure appropriate oversight to hold insurers accountable to ensure patients have timely access to the right care, in the right setting, by the most appropriate health care provider. The following documents represent the Alliance’s position on issues related to narrow networks:
The current structure of Medicare restricts the ability of seniors to see the physician of their choice by limiting beneficiary access to all physicians. One way patients can overcome this hurdle is to “privately contract” for services directly with their physicians. Unfortunately, under current law, beneficiaries who wish to enter into these private contracts must pay for the service entirely out of their own pocket, despite having paid into Medicare for many years. Furthermore, if a physician has “opted out” of Medicare to contract privately — with even one patient — the physician is ineligible for Medicare reimbursement for two years. Congress should eliminate the two‐year Medicare exclusion for physicians who privately contract and allow patients who privately contract to recoup the amount Medicare would otherwise pay for the service. The following documents represent the Alliance’s position on the issue of private contracting:
Fair Medicare Physician Reimbursement
Americans should have a range of coverage options whether they get their health care in the private market, through an exchange plan, or under the Medicaid or Medicare programs. The Alliance of Specialty Medicine urges Congress to maintain a viable fee-for-service (FFS) option in Part B, along with the Merit-based Incentive Payment System (MIPS) program and reject the Medicare Payment Advisory Commission’s (MedPAC) recommendation to replace MIPS with a program not relevant to specialists. Maintaining a viable fee-for-service option in Medicare Part B is necessary, as it is the most appropriate reimbursement structure for many specialists and will help to preserve patient access to the unique services offered by specialists. Furthermore, MIPS is the only meaningful and viable pathway for many specialists to engage in the Quality Payment Program established under MACRA.
The Alliance of Specialty Medicine also believes that the physician self-referral (a.k.a. “Stark”) law must be modernized, to permit physicians to participate and succeed with the intent behind the Medicare Access and CHIP Reauthorization Act (MACRA) – to collaborate within and across specialties to improve patient care, lower costs, and improve efficiencies within the health care system.
The following documents represent the Alliance’s position on the issue of fair Medicare physician reimbursement:
- Issue Brief: Maintain a Viable Fee-For-Service Option & the Merit-based Incentive Payment System (MIPS) program
- Testimony of Dr. Parag Parekh, “MACRA and MIPS: An Update on the Merit-based Incentive Payment System
- Testimony for the Record, Implementation of MACRA’s Physician Payment Policies
Promoting transparency, accountability and oversight must be an integral part of our health care system.
As Congress works to develop consensus policy to address issues arising from out of network care, which can lead to surprise bills, the Alliance of Specialty Medicine urges Congress to avoid unintended and harmful consequences for patients, providers, and the overall health care system. The American Medical Association has outlined the following principles to be considered when developing legislation that seeks to protect patients from out-of-network costs not covered by their health plan: insurer accountability, limit patient responsibility, keep patients out of the middle, transparency, set benchmark payments, alternative dispute resolution, and universality.
Physicians are well positioned to understand the complexities of medical and nonmedical opioid use and to lead change in safe ways that do not marginalize segments of the population through reactionary policies and actions. While many non- opioid analgesics exist and use of these should be optimized moving forward, physicians must help guide policymakers regarding the valid and necessary roles for opioids. In the 115th Congress, the Alliance submitted its comments on a package of legislative approaches to combat opioid abuse and was pleased to see many of these provisions signed into law.
Physicians are on the front lines of the current affordability crisis. Patients are asked to shoulder ever-increasing out-of-pocket obligations, putting critically needed medicines out of reach for many. This directly affects the practice of medicine and physicians’ ability to care for our patients. The Alliance believes in increasing transparency across the drug supply chain. We have testified before Congress and provided input to the Administration about various policies related to drug pricing, which can be found here:
The following documents represent the Alliance’s position on issues related to accountability and transparency:
- Issue Brief (USPSTF Transparency and Accountability Act)
- Testimony for the Record, Efforts to Combat Waste, Fraud, and Abuse in the Medicare Program
The Alliance of Specialty Medicine supports the bipartisan effort to improve the discovery, development and delivery of continued innovation in our health care system. Specialty physicians encourage support for medical innovation that integrates the patient’s perspective into the regulatory process; facilitates responsible communication of scientific and medical developments; modernizes clinical trials; fosters the future of science, including encouraging young scientists; invests in advancing research; incentivizes the development of new drugs and devices for unmet medical needs; promotes interoperability; and supports 21st Century digital medicine by facilitating data sharing and the use of new technologies.
Workforce/Graduate Medical Education (GME)
An appropriate supply of well-educated and trained physicians — both in specialty and primary care — is essential to ensure access to quality health care services for all Americans. The growing physician workforce shortage must be addressed to maintain a workforce that is of sufficient size and specialty mix. The Alliance of Specialty Medicine supports increasing the number of federally funded residency slots to address workforce shortages in many specialties and eliminating the current GME funding restrictions.
According to a 2019 report by the Association of American Medical Colleges (AAMC), the United States will face an overall shortage of up to 121,900 physicians by 2032. Specialty shortages will be particularly large, including neurosurgeons, urologists, cardiologists, gastroenterologists, plastic and reconstructive surgeons, orthopaedic surgeons, and general surgeons. A 2016 report by the Health Resources and Services Administration (HRSA) found that by 2025, ophthalmology and orthopedic surgery are each expected to need more than 5,000 physicians over current levels, while urology will see a shortfall of 3,630 physicians and general surgery a shortage of 2,970.
As a nation, we pride ourselves on having the best medical care has to offer. Specialists are an integral part of American medicine. Regardless of what insurance product people have, Americans want to know they may see their doctor of choice when needed. However, we cannot take for granted that those specialists will be there. Specialty physicians require up to seven years of post-graduate residency training. By the time this crisis further manifests itself, we will be unable to quickly correct it. With 10,000 seniors aging into the Medicare program every day, the need for specialist services will increase significantly. The Alliance of Specialty Medicine urges Congress to take steps now to address the workforce shortages in many specialties and ensure a fully trained specialty physician workforce for the future.
The following documents represent the Alliance’s position on workforce/GME related issues:
- Issue Brief (Resident Physician Shortage Reduction Act)
- Letter in support of the Building a Health Care Workforce for the Future Act (S. 3095 in the 115th Congress)